Algae-Derived Bioactives Reprogram the Gut-SIRT1-Kisspeptin Axis in Polycystic Ovary Syndrome
This review proposes that algae-derived bioactives may act through a gut-SIRT1-kisspeptin axis in polycystic ovary syndrome, linking gut dysbiosis, reduced SIRT1 activity, and dysregulated kisspeptin signaling. The authors integrate evidence that these compounds have prebiotic, anti-inflammatory, and metabolic regulatory properties, but note that direct experimental validation of the complete pathway remains limited.
Researchers studying Kisspeptin would value this paper because it situates kisspeptin signaling within a broader gut-SIRT1-kisspeptin axis and proposes that algae-derived bioactives could retune kisspeptin-driven neuroendocrine activity in PCOS. It does not establish that these compounds affect kisspeptin in humans; it offers a testable conceptual model rather than empirical proof.
Key findings
Gut dysbiosis in PCOS contributes to altered bile acid signaling, disrupted microbial metabolite profiles, and increased inflammatory tone, impairing both metabolic and reproductive functions.
Reduced activity of the NAD+-dependent deacetylase SIRT1 has been documented across ovarian, endometrial, and metabolic tissues, linking energy imbalance to oxidative stress, inflammation, and impaired steroidogenesis.
Dysregulated kisspeptin signaling contributes to abnormal gonadotropin-releasing hormone pulsatility and luteinizing hormone hypersecretion, key features of PCOS.
Algae-derived compounds exhibit prebiotic, anti-inflammatory, and metabolic regulatory properties, particularly through modulation of gut microbiota and activation of AMPK/SIRT1 signaling.
Direct experimental validation of the complete gut-SIRT1-kisspeptin axis remains limited, so the framework is hypothesis-driven rather than established.
Limitations
The authors state that direct experimental validation of the complete pathway remains limited.
The framework is positioned as a hypothesis-driven model integrating currently fragmented findings.
As a review article, it provides no new primary experimental or clinical data to establish causality.
The abstract does not report quantitative effect sizes or clinical outcomes.